CCR8 Antibodies and Fusion Proteins for Cancer Treatment

Fri, 10 Apr 2026 01:20:46 +0000
Intellectual Property

The USPTO published patent application US20260098098A1 covering CCR8-binding antibodies and fusion proteins for cancer treatment. Inventors McGrath et al. filed Application No. 19182473 on April 17, 2025, with the application published on April 9, 2026. The patent covers therapeutic compositions and methods using CCR8-targeted biologics.